Status:
COMPLETED
Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study
Lead Sponsor:
Wanwarang Wongcharoen, MD.
Conditions:
Coronary Artery Bypass Grafting
Eligibility:
All Genders
Phase:
NA
Brief Summary
It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myoc...
Eligibility Criteria
Inclusion
- Patients undergoing CABG without valve surgery
Exclusion
- emergency cardiac surgery
- any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization
- patients with cholestatic jaundice (total bilirubin \> 2-fold ULN)
- severe liver disease (AST or ALT \> 3-fold ULN)
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01528514
Start Date
September 1 2009
End Date
December 1 2012
Last Update
September 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maharaj Nakorn Chiang Mai hospital
Chiang Mai, Thailand, 50210